Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 111–120 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 111
- Medicine slug
- arformoterol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
26 hours
- Numeric value
- 26
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6838a595-19cc-454a-96b9-ff83b93881ae (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8843369-b0d5-6f0d-1fcd-0c49002df755 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf1f2d1b-0455-4113-9647-507faf49fdd0 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c0d81db-fbf5-405f-9311-d3d78992d9a3 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e06ee1-f9d6-5167-e063-6394a90a6d32 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9eb1ac7-57aa-4ef8-aac3-14def5b883d0 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a498c49-042f-481f-bc5c-a2fc00dc5668 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1a6643-f280-4f02-a824-0428a2b82d3c (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2feda53-54b9-4e40-8a01-9e7b45cb3d8c (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9572582e-8cc2-4d3d-b9dc-c2b8159d71d8 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70071afd-5323-4019-aca5-5534278829dc (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1005878-0c48-4b9a-843e-b6cf6b8bb251 (opens source in a new tab)
Arformoterol label
Version not recorded · Effective date not recorded
In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
Projected row 112
- Medicine slug
- argatroban
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
20%
- Numeric value
- 20
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5ccb93c-f411-4e7e-824a-4a592b4947ec (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546484ed-afab-b47b-e063-6394a90aa52d (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50e21062-f021-40f2-ad11-896f46378a15 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4e5238f-2378-424e-bda2-f1a2cf874041 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b975bd-e3f4-466e-96ca-7bef7899506d (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46cdf9e6-839c-49c8-9ee1-c30cfdd9368d (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 – acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0dedf95-8395-46bf-b94a-dcf2dd085942 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α1-acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a67a87d-59cb-414c-a11e-ab8f0a9bb778 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79eec27d-ac63-4996-8b1a-c2cd52ad2b2c (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa5d325-f609-4c9a-aaae-1a17df47da1e (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dedef330-555a-46b7-b1d6-0838b4cd9651 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:514ad15b-d060-9d65-e063-6294a90a6188 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5143563-ff45-433a-a9e2-f8b8340db1f5 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α1-acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cdf3f67-5bf3-4d58-b330-03febdc652bf (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41f56fe7-4824-4032-aa73-cfb4f8db2252 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:629aee90-3bf3-4947-a978-21cbba2e1c41 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:270dbb59-e080-4a64-91d9-a68bed4bd2e5 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
Argatroban is 54% bound to human serum proteins, with binding to albumin and α 1 -acid glycoprotein being 20% and 34%, respectively.
Projected row 113
- Medicine slug
- argatroban
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
12.18 L
- Numeric value
- 12.18
- Unit
- L
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5ccb93c-f411-4e7e-824a-4a592b4947ec (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546484ed-afab-b47b-e063-6394a90aa52d (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50e21062-f021-40f2-ad11-896f46378a15 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4e5238f-2378-424e-bda2-f1a2cf874041 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution: Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b975bd-e3f4-466e-96ca-7bef7899506d (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution: Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46cdf9e6-839c-49c8-9ee1-c30cfdd9368d (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0dedf95-8395-46bf-b94a-dcf2dd085942 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a67a87d-59cb-414c-a11e-ab8f0a9bb778 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution: Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79eec27d-ac63-4996-8b1a-c2cd52ad2b2c (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa5d325-f609-4c9a-aaae-1a17df47da1e (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dedef330-555a-46b7-b1d6-0838b4cd9651 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution: Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:514ad15b-d060-9d65-e063-6294a90a6188 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extra cellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5143563-ff45-433a-a9e2-f8b8340db1f5 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70-kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cdf3f67-5bf3-4d58-b330-03febdc652bf (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41f56fe7-4824-4032-aa73-cfb4f8db2252 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:629aee90-3bf3-4947-a978-21cbba2e1c41 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:270dbb59-e080-4a64-91d9-a68bed4bd2e5 (opens source in a new tab)
Argatroban label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Argatroban distributes mainly in the extracellular fluid as evidenced by an apparent steady-state volume of distribution of 174 mL/kg (12.18 L in a 70 kg adult).
Projected row 114
- Medicine slug
- aripiprazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 118
- Source count
- 104
- Agreement rate
- 1
- Recorded readings
87%
- Numeric value
- 87
- Unit
- %
- Source records
- 104
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 104 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a10a5427-58b1-42dd-964c-3f8c78770534 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7040fef-96a7-4429-9a8e-ec3ab17a8019 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0f910b5-adef-4a93-9369-70f1ed541503 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95954ba3-e838-4dd7-aef1-c51ac6aff76b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bc00231-c2e7-4b9d-93a1-fb796fd8d591 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52cc86ba-2c4f-1aba-e063-6294a90a844e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573c6bb6-941f-4413-8c23-826025385864 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f713c38e-cc49-4243-96b9-32d5dbbcf9cb (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bf7d35e-46a1-4e8f-aeb5-8a93223a4abc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50214c47-2ea3-b373-e063-6394a90aad23 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13339e7f-a8b4-430d-b623-47372de98348 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbb3ac69-8dba-42df-8d6d-ef3d79241edb (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d8d574b-fbf4-4d2c-a37c-25556ecbf1aa (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e8d889e-126b-4627-a2cc-34f2d35a5d67 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7d9d5d1-25ba-4f4e-a990-398c0bf09c7e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b284b294-40a0-4ccd-b7b7-b61267cd4e76 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:969c17aa-6abc-413c-8561-f1ad8fdde3e5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e0d42ad-f4c6-4e30-adc2-ab1d122428ec (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ad7d167-1235-4c5c-8159-da8972240ede (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47430dfa-9377-6c31-e063-6394a90a86a9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:433cdc7d-465a-4ad4-bd84-cabd37e15f51 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb40b669-4e37-4087-8fb1-3ac140543602 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3c0be94-c6c0-47e2-892f-c51f100fb3a3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db6fc74e-4989-464d-9c19-a5b7a541fd46 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2fa4da-2ee9-4965-b1f8-ce1c8b73ba93 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbdc8fbe-c75f-4f17-a2cd-9f23802dcc5d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34127431-6ad7-402f-bc22-1429c55d921c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:385301f5-e59d-42d5-8544-aadf0ee0c967 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff8dc838-ca1a-49d3-8938-5ae645574a75 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1691a8-724e-430d-9bab-27b59ef9bd4e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b695d4b-3794-4b89-8575-6feb83697ccc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbfc8f-fa17-839e-e063-6394a90a6316 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:119e3387-39a2-4fe5-904b-c2d008425c0a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf6655e-d59a-4ebd-9698-195cad2adbd5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c040bd1d-45b7-49f2-93ea-aed7220b30ac (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f87dbfe4-5417-47c9-a97f-d246cfc10023 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf3cf835-4c4e-47cb-be9c-bcb7c2e11cbe (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f823bc23-27f3-2397-e053-6294a90a365a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a6fa113-6bb2-4f88-af07-ce0914c98ff2 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178f09f0-e08e-452b-b817-717c5c49e110 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:535f4fbd-b6a7-7611-e063-6294a90a5c43 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3718e585-06b9-40fd-a3eb-18b6497a4235 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aa7e178-456a-4942-93aa-9ec18a58939f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:476b92f3-cf7b-4c09-ac67-6ed35e6811d5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35a86989-862e-b0bb-e063-6394a90a7ec1 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19a3c2f2-11eb-4ec9-ac38-134168bdf99c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b62837db-1949-4dba-9e2f-714a9f136f5a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27874fe2-3fd6-002d-e063-6294a90a4cd7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faa3032b-d9a1-45dd-88be-abb432223f13 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f3a705-9412-0f88-e063-6294a90a2b53 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3988e66f-339c-451e-9f8a-9d0c0a2a381b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab3973f3-3db8-4db2-8258-1b21af7b6380 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d130836c-5f1c-4779-ac6c-6350752dc015 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c5e380-b7b1-4362-a827-71881574ff48 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf72cc6-ae43-bfd5-e063-6294a90a18b0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7df4c83e-13d8-25b1-57eb-08d26ba03565 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef9e44f-5672-47c2-97e9-286e1b84417d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d593ada-256d-4dec-9a26-2a6a67d97205 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc3fde41-2f24-44e2-815d-15fe55bd68b3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abb8ad7e-7998-4485-a09f-a2892190f4ad (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8da99c93-613e-4b78-9f91-3efc2dea194d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facdb9a9-612f-e59a-e053-6394a90a1fa7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2dc5fd-ecb4-4445-9cfb-10e64fe3269d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cc7d25-414b-4b6f-a03a-48af908a16a1 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:554db933-aa80-4685-bcd5-58c84571c19c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bda6f17-d87c-4009-b329-99275c56106f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69af5199-f872-4298-8d09-035e2127d3d4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506fa28f-6f98-4632-bce8-72a9cb507c90 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36fb0c13-dfae-46ac-bb71-0b53fe5649f4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8edb057-18a3-446d-8af0-672c97933a88 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96172aa4-9e13-4eca-83d5-85a88c1782d3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd81df7-8482-493e-bfc5-a3352f466b9e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11202c0a-7401-41c9-b1e7-d93739fcd36f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89c2cddc-2ae3-4505-adf9-018542c713bf (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ab6af7c-3169-46bf-bd3f-697c81bbcede (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf7dc7e-04f3-442b-86d7-5f54d17d102c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b0c3767-d397-4c7f-b229-083620d9ae6b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3726d102-dd9f-645e-e063-6294a90aeb9e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:686d0088-ac61-41df-8909-ae12f7957644 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02a4af27-c83c-4166-950c-7a1cb12d198d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:512874e6-6d00-2623-e063-6394a90aa4bc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c092a736-16e2-4dd0-8769-cb766a62f4d9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1191a90-eb83-4a59-948c-b9774d2c83a5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f446b0-caa2-aca8-e063-6294a90af441 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793fc904-2f11-4f97-a0ac-4d6910cac0f9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee33be35-abc8-453f-98e9-7974026b7eb0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f81d9b82-5879-3c0a-e053-6294a90ac23e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349b8a7b-5ada-4f5c-a269-a86806c6b520 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99747897-22fe-4bee-9942-6349c0c8f6b0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab4245a1-71f7-45be-a2ef-b0636ed3cc20 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06dda03f-8481-46d6-af02-4f51e1a3a065 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4894031e-639e-49d8-927a-76d684bf6655 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:720bc395-777d-4e5d-9571-aad5827dbf6d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c0109f6-0549-4f91-a259-d9d6d7329b91 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8a94428-b6d2-428b-a3a5-7b983d572fab (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7b6a156-8001-441c-bfd3-bf8987a339e8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcea91c3-e428-8991-e053-6394a90a099d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2b0172-b186-4be4-a002-4a26adf120c6 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:414b7fd2-6a63-af39-e063-6394a90a00b8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:705190bf-9f9d-4183-a56b-4eeafeacde59 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f580e75-61ab-4c7b-bb3f-f027a9603f84 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56439ef6-a07e-34c9-e063-6294a90a77c3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
Projected row 115
- Medicine slug
- aripiprazole
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 118
- Source count
- 116
- Agreement rate
- 0.991379
- Recorded readings
146 hours
- Numeric value
- 146
- Unit
- hours
- Source records
- 115
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 115 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b47ede68-8942-4432-af7e-57afc14b2ba4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a10a5427-58b1-42dd-964c-3f8c78770534 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7040fef-96a7-4429-9a8e-ec3ab17a8019 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0f910b5-adef-4a93-9369-70f1ed541503 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95954ba3-e838-4dd7-aef1-c51ac6aff76b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bc00231-c2e7-4b9d-93a1-fb796fd8d591 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52cc86ba-2c4f-1aba-e063-6294a90a844e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573c6bb6-941f-4413-8c23-826025385864 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f713c38e-cc49-4243-96b9-32d5dbbcf9cb (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bf7d35e-46a1-4e8f-aeb5-8a93223a4abc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50214c47-2ea3-b373-e063-6394a90aad23 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13339e7f-a8b4-430d-b623-47372de98348 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbb3ac69-8dba-42df-8d6d-ef3d79241edb (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d8d574b-fbf4-4d2c-a37c-25556ecbf1aa (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e8d889e-126b-4627-a2cc-34f2d35a5d67 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7d9d5d1-25ba-4f4e-a990-398c0bf09c7e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b284b294-40a0-4ccd-b7b7-b61267cd4e76 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:969c17aa-6abc-413c-8561-f1ad8fdde3e5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e0d42ad-f4c6-4e30-adc2-ab1d122428ec (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ad7d167-1235-4c5c-8159-da8972240ede (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:433cdc7d-465a-4ad4-bd84-cabd37e15f51 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb40b669-4e37-4087-8fb1-3ac140543602 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3c0be94-c6c0-47e2-892f-c51f100fb3a3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db6fc74e-4989-464d-9c19-a5b7a541fd46 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2fa4da-2ee9-4965-b1f8-ce1c8b73ba93 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbdc8fbe-c75f-4f17-a2cd-9f23802dcc5d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34127431-6ad7-402f-bc22-1429c55d921c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:385301f5-e59d-42d5-8544-aadf0ee0c967 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff8dc838-ca1a-49d3-8938-5ae645574a75 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1691a8-724e-430d-9bab-27b59ef9bd4e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b695d4b-3794-4b89-8575-6feb83697ccc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbfc8f-fa17-839e-e063-6394a90a6316 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:119e3387-39a2-4fe5-904b-c2d008425c0a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf6655e-d59a-4ebd-9698-195cad2adbd5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c040bd1d-45b7-49f2-93ea-aed7220b30ac (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f87dbfe4-5417-47c9-a97f-d246cfc10023 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf3cf835-4c4e-47cb-be9c-bcb7c2e11cbe (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f823bc23-27f3-2397-e053-6294a90a365a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f272100-e02f-4a16-bb39-a2bf844db4f9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a6fa113-6bb2-4f88-af07-ce0914c98ff2 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7292c4c-e332-4ed4-9086-f130d223b6ae (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178f09f0-e08e-452b-b817-717c5c49e110 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:535f4fbd-b6a7-7611-e063-6294a90a5c43 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3718e585-06b9-40fd-a3eb-18b6497a4235 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aa7e178-456a-4942-93aa-9ec18a58939f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:476b92f3-cf7b-4c09-ac67-6ed35e6811d5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35a86989-862e-b0bb-e063-6394a90a7ec1 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19a3c2f2-11eb-4ec9-ac38-134168bdf99c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b62837db-1949-4dba-9e2f-714a9f136f5a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27874fe2-3fd6-002d-e063-6294a90a4cd7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faa3032b-d9a1-45dd-88be-abb432223f13 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14910dae-da81-3d73-d0a4-e98d13917c69 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f3a705-9412-0f88-e063-6294a90a2b53 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3988e66f-339c-451e-9f8a-9d0c0a2a381b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06529caf-698f-41da-81ec-d0ba5ab200d7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab3973f3-3db8-4db2-8258-1b21af7b6380 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d130836c-5f1c-4779-ac6c-6350752dc015 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c5e380-b7b1-4362-a827-71881574ff48 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf72cc6-ae43-bfd5-e063-6294a90a18b0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7df4c83e-13d8-25b1-57eb-08d26ba03565 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef9e44f-5672-47c2-97e9-286e1b84417d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d593ada-256d-4dec-9a26-2a6a67d97205 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc3fde41-2f24-44e2-815d-15fe55bd68b3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abb8ad7e-7998-4485-a09f-a2892190f4ad (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8da99c93-613e-4b78-9f91-3efc2dea194d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facdb9a9-612f-e59a-e053-6394a90a1fa7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2dc5fd-ecb4-4445-9cfb-10e64fe3269d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cc7d25-414b-4b6f-a03a-48af908a16a1 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4537e26b-dcf8-4a78-ab7d-57359b1d2192 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:554db933-aa80-4685-bcd5-58c84571c19c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bda6f17-d87c-4009-b329-99275c56106f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69af5199-f872-4298-8d09-035e2127d3d4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:042b725c-1c17-4cfb-80b2-c841226d795e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506fa28f-6f98-4632-bce8-72a9cb507c90 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36fb0c13-dfae-46ac-bb71-0b53fe5649f4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8edb057-18a3-446d-8af0-672c97933a88 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96172aa4-9e13-4eca-83d5-85a88c1782d3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd81df7-8482-493e-bfc5-a3352f466b9e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11202c0a-7401-41c9-b1e7-d93739fcd36f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89c2cddc-2ae3-4505-adf9-018542c713bf (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ab6af7c-3169-46bf-bd3f-697c81bbcede (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf7dc7e-04f3-442b-86d7-5f54d17d102c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a0a2f6c-d7bb-48d1-b5ca-066f27f78e41 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b0c3767-d397-4c7f-b229-083620d9ae6b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3726d102-dd9f-645e-e063-6294a90aeb9e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:686d0088-ac61-41df-8909-ae12f7957644 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02a4af27-c83c-4166-950c-7a1cb12d198d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:512874e6-6d00-2623-e063-6394a90aa4bc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c092a736-16e2-4dd0-8769-cb766a62f4d9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1191a90-eb83-4a59-948c-b9774d2c83a5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f446b0-caa2-aca8-e063-6294a90af441 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793fc904-2f11-4f97-a0ac-4d6910cac0f9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee33be35-abc8-453f-98e9-7974026b7eb0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcabd777-dcb7-452c-821c-575a5991c90a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f81d9b82-5879-3c0a-e053-6294a90ac23e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b12f1ff2-c0b5-47e7-8075-bf2ce79fdaf8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349b8a7b-5ada-4f5c-a269-a86806c6b520 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99747897-22fe-4bee-9942-6349c0c8f6b0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab4245a1-71f7-45be-a2ef-b0636ed3cc20 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06dda03f-8481-46d6-af02-4f51e1a3a065 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4894031e-639e-49d8-927a-76d684bf6655 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:720bc395-777d-4e5d-9571-aad5827dbf6d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c0109f6-0549-4f91-a259-d9d6d7329b91 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8a94428-b6d2-428b-a3a5-7b983d572fab (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7b6a156-8001-441c-bfd3-bf8987a339e8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcea91c3-e428-8991-e053-6394a90a099d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da47ad78-e62c-4bf3-9b53-d8cc246bcfb6 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d27462e-45c7-4335-9092-84c340e06a2c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2b0172-b186-4be4-a002-4a26adf120c6 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:414b7fd2-6a63-af39-e063-6394a90a00b8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:705190bf-9f9d-4183-a56b-4eeafeacde59 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f580e75-61ab-4c7b-bb3f-f027a9603f84 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56439ef6-a07e-34c9-e063-6294a90a77c3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
21 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da4c07fd-1130-4341-bb44-63acfa4162be (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Elimination Following single dose administration of ABILIFY ASIMTUFII, the mean apparent terminal elimination half-life of aripiprazole was 21 days.
Projected row 116
- Medicine slug
- aripiprazole
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 118
- Source count
- 104
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 104
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 104 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a10a5427-58b1-42dd-964c-3f8c78770534 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7040fef-96a7-4429-9a8e-ec3ab17a8019 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0f910b5-adef-4a93-9369-70f1ed541503 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95954ba3-e838-4dd7-aef1-c51ac6aff76b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bc00231-c2e7-4b9d-93a1-fb796fd8d591 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52cc86ba-2c4f-1aba-e063-6294a90a844e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:573c6bb6-941f-4413-8c23-826025385864 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f713c38e-cc49-4243-96b9-32d5dbbcf9cb (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bf7d35e-46a1-4e8f-aeb5-8a93223a4abc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50214c47-2ea3-b373-e063-6394a90aad23 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13339e7f-a8b4-430d-b623-47372de98348 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbb3ac69-8dba-42df-8d6d-ef3d79241edb (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d8d574b-fbf4-4d2c-a37c-25556ecbf1aa (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e8d889e-126b-4627-a2cc-34f2d35a5d67 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7d9d5d1-25ba-4f4e-a990-398c0bf09c7e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b284b294-40a0-4ccd-b7b7-b61267cd4e76 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:969c17aa-6abc-413c-8561-f1ad8fdde3e5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e0d42ad-f4c6-4e30-adc2-ab1d122428ec (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ad7d167-1235-4c5c-8159-da8972240ede (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47430dfa-9377-6c31-e063-6394a90a86a9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:433cdc7d-465a-4ad4-bd84-cabd37e15f51 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb40b669-4e37-4087-8fb1-3ac140543602 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3c0be94-c6c0-47e2-892f-c51f100fb3a3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db6fc74e-4989-464d-9c19-a5b7a541fd46 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2fa4da-2ee9-4965-b1f8-ce1c8b73ba93 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbdc8fbe-c75f-4f17-a2cd-9f23802dcc5d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34127431-6ad7-402f-bc22-1429c55d921c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:385301f5-e59d-42d5-8544-aadf0ee0c967 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff8dc838-ca1a-49d3-8938-5ae645574a75 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1691a8-724e-430d-9bab-27b59ef9bd4e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b695d4b-3794-4b89-8575-6feb83697ccc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbfc8f-fa17-839e-e063-6394a90a6316 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:119e3387-39a2-4fe5-904b-c2d008425c0a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf6655e-d59a-4ebd-9698-195cad2adbd5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c040bd1d-45b7-49f2-93ea-aed7220b30ac (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f87dbfe4-5417-47c9-a97f-d246cfc10023 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf3cf835-4c4e-47cb-be9c-bcb7c2e11cbe (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f823bc23-27f3-2397-e053-6294a90a365a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a6fa113-6bb2-4f88-af07-ce0914c98ff2 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178f09f0-e08e-452b-b817-717c5c49e110 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:535f4fbd-b6a7-7611-e063-6294a90a5c43 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3718e585-06b9-40fd-a3eb-18b6497a4235 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aa7e178-456a-4942-93aa-9ec18a58939f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:476b92f3-cf7b-4c09-ac67-6ed35e6811d5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35a86989-862e-b0bb-e063-6394a90a7ec1 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19a3c2f2-11eb-4ec9-ac38-134168bdf99c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b62837db-1949-4dba-9e2f-714a9f136f5a (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27874fe2-3fd6-002d-e063-6294a90a4cd7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faa3032b-d9a1-45dd-88be-abb432223f13 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f3a705-9412-0f88-e063-6294a90a2b53 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3988e66f-339c-451e-9f8a-9d0c0a2a381b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab3973f3-3db8-4db2-8258-1b21af7b6380 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d130836c-5f1c-4779-ac6c-6350752dc015 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c5e380-b7b1-4362-a827-71881574ff48 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf72cc6-ae43-bfd5-e063-6294a90a18b0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7df4c83e-13d8-25b1-57eb-08d26ba03565 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef9e44f-5672-47c2-97e9-286e1b84417d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d593ada-256d-4dec-9a26-2a6a67d97205 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc3fde41-2f24-44e2-815d-15fe55bd68b3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abb8ad7e-7998-4485-a09f-a2892190f4ad (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8da99c93-613e-4b78-9f91-3efc2dea194d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facdb9a9-612f-e59a-e053-6394a90a1fa7 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2dc5fd-ecb4-4445-9cfb-10e64fe3269d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cc7d25-414b-4b6f-a03a-48af908a16a1 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:554db933-aa80-4685-bcd5-58c84571c19c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bda6f17-d87c-4009-b329-99275c56106f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69af5199-f872-4298-8d09-035e2127d3d4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:506fa28f-6f98-4632-bce8-72a9cb507c90 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36fb0c13-dfae-46ac-bb71-0b53fe5649f4 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8edb057-18a3-446d-8af0-672c97933a88 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96172aa4-9e13-4eca-83d5-85a88c1782d3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd81df7-8482-493e-bfc5-a3352f466b9e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11202c0a-7401-41c9-b1e7-d93739fcd36f (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89c2cddc-2ae3-4505-adf9-018542c713bf (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ab6af7c-3169-46bf-bd3f-697c81bbcede (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf7dc7e-04f3-442b-86d7-5f54d17d102c (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b0c3767-d397-4c7f-b229-083620d9ae6b (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3726d102-dd9f-645e-e063-6294a90aeb9e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:686d0088-ac61-41df-8909-ae12f7957644 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablets: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02a4af27-c83c-4166-950c-7a1cb12d198d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:512874e6-6d00-2623-e063-6394a90aa4bc (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c092a736-16e2-4dd0-8769-cb766a62f4d9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral Administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1191a90-eb83-4a59-948c-b9774d2c83a5 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f446b0-caa2-aca8-e063-6294a90af441 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793fc904-2f11-4f97-a0ac-4d6910cac0f9 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee33be35-abc8-453f-98e9-7974026b7eb0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f81d9b82-5879-3c0a-e053-6294a90ac23e (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:349b8a7b-5ada-4f5c-a269-a86806c6b520 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99747897-22fe-4bee-9942-6349c0c8f6b0 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab4245a1-71f7-45be-a2ef-b0636ed3cc20 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06dda03f-8481-46d6-af02-4f51e1a3a065 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4894031e-639e-49d8-927a-76d684bf6655 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:720bc395-777d-4e5d-9571-aad5827dbf6d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c0109f6-0549-4f91-a259-d9d6d7329b91 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet : Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8a94428-b6d2-428b-a3a5-7b983d572fab (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7b6a156-8001-441c-bfd3-bf8987a339e8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcea91c3-e428-8991-e053-6394a90a099d (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c2b0172-b186-4be4-a002-4a26adf120c6 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:414b7fd2-6a63-af39-e063-6394a90a00b8 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Oral administration Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:705190bf-9f9d-4183-a56b-4eeafeacde59 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
ORAL ADMINISTRATION Absorption Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f580e75-61ab-4c7b-bb3f-f027a9603f84 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56439ef6-a07e-34c9-e063-6294a90a77c3 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
Projected row 117
- Medicine slug
- aripiprazole-lauroxil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
75 hours
- Numeric value
- 75
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
The significantly longer aripiprazole apparent half-life compared to oral aripiprazole (mean 75 hours) is attributed to the dissolution and formation rate-limited elimination of aripiprazole following ARISTADA administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403 (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
The significantly longer aripiprazole apparent half-life compared to oral aripiprazole (mean 75 hours) is attributed to the dissolution and formation rate-limited elimination of aripiprazole following ARISTADA INITIO administration.
Projected row 118
- Medicine slug
- armodafinil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facd329b-1925-61df-e053-6294a90ab738 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the Cmax and AUC0-∞, of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2f0921-e791-426c-9192-2b7162e2158c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil tablets than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cac300-c3d2-4189-a410-2aaf3773c090 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbe7c0d9-dfd2-4000-bd76-7fe3454ce64f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd49302-f757-d945-e063-6294a90afcba (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg NUVIGIL than the corresponding values of modafinil following administration of 200 mg PROVIGIL due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23da56b8-7552-4362-a1ab-e794c131194c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1ba1cdd-cf57-7a8c-e053-2a95a90a2c19 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the Cmax and AUC0-∞, of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4128759d-ed7c-4130-b24c-a0541f2b9e7f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d878aed0-ddbf-8fa1-abf7-d3e480260845 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg NUVIGIL than the corresponding values of modafinil following administration of 200 mg PROVIGIL due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98338994-7818-4b86-ae98-cd08fa700879 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69631d0-1263-769e-b232-4ab9160e0fa3 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg NUVIGIL than the corresponding values of modafinil following administration of 200 mg PROVIGIL due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3341ec8-1ad4-49e2-922b-13d1b30c8c1d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady-state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil than the corresponding values of modafinil following administration of 200 mg modafinil due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0799f7-7644-4057-a7da-75436f978c61 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil tablets than the corresponding values of modafinil following administration of 200 mg PROVIGIL due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e33a21-7816-4fa9-9fc7-c559426ad2b9 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, the C max and AUC 0-∞ , of armodafinil at steady state were approximately 37% and 70% higher, respectively, following administration of 200 mg armodafinil tablets than the corresponding values of modafinil following administration of 200 mg PROVIGIL due to the more rapid clearance of the S-enantiomer (elimination half-life approximately 4 hours) as compared to the R-enantiomer.
Projected row 119
- Medicine slug
- armodafinil
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facd329b-1925-61df-e053-6294a90ab738 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2f0921-e791-426c-9192-2b7162e2158c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cac300-c3d2-4189-a410-2aaf3773c090 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbe7c0d9-dfd2-4000-bd76-7fe3454ce64f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd49302-f757-d945-e063-6294a90afcba (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23da56b8-7552-4362-a1ab-e794c131194c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1ba1cdd-cf57-7a8c-e053-2a95a90a2c19 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4128759d-ed7c-4130-b24c-a0541f2b9e7f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d878aed0-ddbf-8fa1-abf7-d3e480260845 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98338994-7818-4b86-ae98-cd08fa700879 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69631d0-1263-769e-b232-4ab9160e0fa3 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3341ec8-1ad4-49e2-922b-13d1b30c8c1d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0799f7-7644-4057-a7da-75436f978c61 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e33a21-7816-4fa9-9fc7-c559426ad2b9 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin.
Projected row 120
- Medicine slug
- armodafinil
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:facd329b-1925-61df-e053-6294a90ab738 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2f0921-e791-426c-9192-2b7162e2158c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cac300-c3d2-4189-a410-2aaf3773c090 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbe7c0d9-dfd2-4000-bd76-7fe3454ce64f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd49302-f757-d945-e063-6294a90afcba (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23da56b8-7552-4362-a1ab-e794c131194c (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1ba1cdd-cf57-7a8c-e053-2a95a90a2c19 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4128759d-ed7c-4130-b24c-a0541f2b9e7f (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d878aed0-ddbf-8fa1-abf7-d3e480260845 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98338994-7818-4b86-ae98-cd08fa700879 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a69631d0-1263-769e-b232-4ab9160e0fa3 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3341ec8-1ad4-49e2-922b-13d1b30c8c1d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0799f7-7644-4057-a7da-75436f978c61 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e33a21-7816-4fa9-9fc7-c559426ad2b9 (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Peak plasma concentrations are attained at approximately 2 hours in the fasted state.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=110Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.